E
Encore Medical, Inc.
EMIFiledEncore Medical, Inc. · Exchange pending · latest filing 2026-09-28
One-minute decisionBASIC RESEARCHSource completeness · 78%
Encore Medical advances a conditional IPO while losses, liquidity needs, and regulatory execution remain material.
As of the September 28, 2026 S-1/A, Encore Medical proposed a $5.00 IPO for 3,000,000 shares, subject to completion and NYSE American listing.
Capital destination
Awaiting verificationS-1/A · 2026-09-28
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1/A ↗Capital destination
Awaiting verificationS-1/A · 2026-09-28
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · S-1/A ↗BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSEDNames not yet published
Dilution and valuation
IPO priceAwaiting verification
Basic post-offer10,743,425
Fully diluted sharesAwaiting verification
Value—
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer shares · Encore Medical, Inc. | 10,743,425 | — | Immediately after offering; no overallotment · Prospectus Summary |
Basic-price scenario
A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.
Check the source · S-1/A ↗Holder data awaits verification
Officers and directors are expected to retain 27.0% collectively and Joseph Marino with family members approximately 15.5%, based on beneficial ownership rules and no overallotment. Voting rights by holder and sponsor-style holdings are not supplied. Series A conversion is 876,000 shares immediately before closing and is included in post-offering shares. · 2026-09-28
Officers and directors are expected to retain 27.0% collectively and Joseph Marino with family members approximately 15.5%, based on beneficial ownership rules and no overallotment. Voting rights by holder and sponsor-style holdings are not supplied. Series A conversion is 876,000 shares immediately before closing and is included in post-offering shares.
One disclosed holder; not a complete ownership distribution.Check the source · S-1/A ↗Conditional lock-up timeline
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Financial quality and runway
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Latest filing update
Loading saved filing update…
SEC filing history
Loading filing history…
The company has no U.S. marketing approval; failure or delay in the stroke trial and PMA process could prevent U.S. commercialization.
- Potential impact
- Awaiting verification
- Monitor
- Effectiveness, final pricing, closing, listing and trading remain unconfirmed; no verified date is supplied.
- Evidence
- Risk Factors ↗